Skip to main content Accessibility help
×
Home

Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study

  • Vincent Chin-Hung Chen (a1), Hsiang-Lin Chan (a2), Shu-I Wu (a3), Mong-Liang Lu (a4), Michael E. Dewey (a5), Robert Stewart (a6) and Charles Tzu-Chi Lee (a7)...

Abstract

Background

Little is known about methylphenidate (MPH) use and mortality outcomes.

Aims

To investigate the association between MPH use and mortality among children with an attention-deficit hyperactivity disorder (ADHD) diagnosis.

Method

This population-based cohort study analysed data from Taiwan's National Health Insurance Research Database (NHIRD). A total of 68 096 children and adolescents aged 4–17 years with an ADHD diagnosis and prescribed MPH between 2000 and 2010 were compared with 68 096 without an MPH prescription, matched on age, gender and year of first ADHD diagnosis. All participants were followed to death, migration, withdrawal from the National Health Insurance programme or 31 December 2013. MPH prescriptions were measured on a yearly basis during the study period, and the association between MPH use and mortality was analysed using a repeated-measures time-dependent Cox regression model. The outcome measures included all-cause, unnatural-cause (including suicide, accident and homicide) and natural-cause mortality, obtained from linkage to the National Mortality Register in Taiwan.

Results

The MPH group had lower unadjusted all-cause, natural-, unnatural- and accident-cause mortality than the comparison group. After controlling for potential confounders, MPH use was associated with a significantly lower all-cause mortality (adjusted hazard ratio AHR = 0.81, 95% CI 0.67–0.98, P = 0.027), delayed use of MPH was associated with higher mortality (AHR = 1.05, 95% CI 1.01–1.09) and longer MPH use was associated with lower mortality (AHR = 0.83, 95% CI 0.70–0.98).

Conclusions

MPH use is associated with a reduced overall mortality in children with ADHD in this cohort study, but unmeasured confounding cannot be excluded absolutely.

Copyright

Corresponding author

Correspondence: Dr Charles Tzu-Chi Lee. Email: lee@ntnu.edu.tw

References

Hide All
1Polanczyk, GV, Salum, GA, Sugaya, LS, Caye, A, Rohde, LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015; 56: 345–65.
2Kessler, RC, Adler, L, Barkley, R, Biederman, J, Conners, CK, Demler, O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716–23.
3Huang, CL, Chu, CC, Cheng, TJ, Weng, SF. Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. PLoS One 2014; 9(4): e95014.
4Yoshimasu, K, Barbaresi, WJ, Colligan, RC, Voigt, RG, Killian, JM, Weaver, AL, et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population-based birth cohort study. J Child Psychol Psychiatry 2012; 53: 1036–43.
5Balazs, J, Kereszteny, A. Attention-deficit/hyperactivity disorder and suicide: a systematic review. World J Psychiatry 2017; 7: 4459.
6Altun, C, Guven, G, Akgun, OM, Acikel, C. Dental injuries and attention-deficit/hyperactivity disorder in children. Spec Care Dentist 2012; 32: 184–9.
7Ertan, C, Ozcan, OO, Pepele, MS. Paediatric trauma patients and attention deficit hyperactivity disorder: correlation and significance. Emerg Med J 2012; 29: 911–4.
8Tai, YM, Gau, SS, Gau, CS. Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan. Res Dev Disabil 2013; 34: 1100–8.
9Vaa, T. ADHD and relative risk of accidents in road traffic: a meta-analysis. Accid Anal Prev 2014; 62: 415–25.
10Curry, AE, Metzger, KB, Pfeiffer, MR, Elliott, MR, Winston, FK, Power, TJ. Motor vehicle crash risk among adolescents and young adults with attention-deficit/hyperactivity disorder. JAMA Pediatrics 2017; 171: 756–63.
11Barbaresi, WJ, Colligan, RC, Weaver, AL, Voigt, RG, Killian, JM, Mortality, KS. ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics 2013; 131: 637–44.
12Dalsgaard, S, Ostergaard, SD, Leckman, JF, Mortensen, PB, Pedersen, MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385: 2190–6.
13London, AS, Landes, SD. Attention deficit hyperactivity disorder and adult mortality. Prev Med 2016; 90: 810.
14Chen, VC, Chan, HL, Wu, SI, Lee, M, Lu, ML, Liang, HY, et al. Attention-deficit/hyperactivity disorder and mortality risk in Taiwan. JAMA Network Open 2019; 2(8): e198714.
15Cairney, J. Deficits in attention, motor control, and perception and increased risk of injury in children. Dev Med Child Neurol 2014; 56: 1040–1.
16Jerome, L, Habinski, L, Segal, A. Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique. Curr Psychiatry Rep 2006; 8: 416–26.
17Vaughan, B, Kratochvil, CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2012; 21: 941–55.
18MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86.
19Man, KK, Chan, EW, Coghill, D, Douglas, I, Ip, P, Leung, LP, et al. Methylphenidate and the risk of trauma. Pediatrics 2015; 135: 40–8.
20Mikolajczyk, R, Horn, J, Schmedt, N, Langner, I, Lindemann, C, Garbe, E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA Pediatrics 2015; 169: 391–5.
21Chang, Z, Quinn, PD, Hur, K, Gibbons, RD, Sjolander, A, Larsson, H, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017; 74: 597603.
22Ruiz-Goikoetxea, M, Cortese, S, Aznarez-Sanado, M, Magallon, S, Alvarez Zallo, N, Luis, EO, et al. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis. Neurosci Biobehav Rev 2018; 84: 6371.
23Ljung, T, Chen, Q, Lichtenstein, P, Larsson, H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. JAMA Psychiatry 2014; 71: 958–64.
24Liang, SH, Yang, YH, Kuo, TY, Liao, YT, Lin, TC, Lee, Y, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil 2018; 72: 96105.
25Cortese, S, Adamo, N, Del Giovane, C, Mohr-Jensen, C, Hayes, AJ, Carucci, S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727–38.
26Storebo, OJ, Pedersen, N, Ramstad, E, Kielsholm, ML, Nielsen, SS, Krogh, HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev 2018; 5: CD012069.
27Dalsgaard, S, Kvist, AP, Leckman, JF, Nielsen, HS, Simonsen, M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 2014; 24: 302–10.
28Mazza, M, D'Ascenzo, F, Davico, C, Biondi-Zoccai, G, Frati, G, Romagnoli, E, et al. Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies. Int J Cardiol 2013; 168: 4320–1.
29Chang, Z, Ghirardi, L, Quinn, PD, Asherson, P, D'Onofrio, BM, Larsson, H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 2019; 86: 335–43.
30Olfson, M, Druss, BG, Marcus, SC. Trends in mental health care among children and adolescents. N Engl J Med 2015; 373: 1079.
31Hechtman, L. Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep 2006; 8: 398408.
32McCarthy, S, Cranswick, N, Potts, L, Taylor, E, Wong, IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009; 32: 1089–96.
33Chen, Q, Sjolander, A, Runeson, B, D'Onofrio, BM, Lichtenstein, P, Larsson, H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348: g3769.
34Kaur, P, Muthuraman, A, Kaur, M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci 2015; 6: 508–21.
35Lee, MJ, Yang, KC, Shyu, YC, Yuan, SS, Yang, CJ, Lee, SY, et al. Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population-based study in Taiwan. J Affect Disord 2016; 189: 110–7.
36Ngwa, JS, Cabral, HJ, Cheng, DM, Pencina, MJ, Gagnon, DR, LaValley, MP, et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol 2016; 16: 148.
37Gray, B. cmprsk: Subdistribution Analysis of Competing Risks. CRAN, 2014 (https://cran.r-project.org/web/packages/cmprsk/index.html).
38Fine, JP, Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
39R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2019 (https://www.R-project.org/).
40Berger, S. Attention deficit hyperactivity disorder medications in children with heart disease. Curr Opin Pediatr 2016; 28: 607–12.
41Shin, JY, Roughead, EE, Park, BJ, Pratt, NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 2016; 353: i2550.
42Winterstein, AG, Gerhard, T, Kubilis, P, Saidi, A, Linden, S, Crystal, S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345: e4627.
43Man, KKC, Ip, P, Chan, EW, Law, SL, Leung, MTY, Ma, EXY, et al. Effectiveness of pharmacological treatment for attention-deficit/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies. CNS Drugs 2017; 31: 1043–55.
44Chen, VC, Yang, YH, Liao, YT, Kuo, TY, Liang, HY, Huang, KY, et al. The association between methylphenidate treatment and the risk for fracture among young ADHD patients: a nationwide population-based study in Taiwan. PLoS One 2017; 12(3): e0173762.
45Mannuzza, S, Klein, RG, Truong, NL, Moulton, JL 3rd, Roizen, ER, Howell, KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165: 604–9.
46Lee, CT, Chen, VC, Tan, HK, Chou, SY, Wu, KH, Chan, CH, et al. Suicide and other-cause mortality among heroin users in Taiwan: a prospective study. Addict Behav 2013; 38: 2619–23.
47Russell, AE, Ford, T, Russell, G. Barriers and predictors of medication use for childhood ADHD: findings from a UK population-representative cohort. Soc Psychiatry Psychiatr Epidemiol 2019; 54: 1555–64.
48Rucklidge, JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010; 33: 357–73.
49Lichtenstein, P, Larsson, H. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2013; 368: 776.

Keywords

Type Description Title
UNKNOWN
Supplementary materials

Chen et al. Supplementary Materials
Chen et al. Supplementary Materials

 Unknown (8.3 MB)
8.3 MB

Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study

  • Vincent Chin-Hung Chen (a1), Hsiang-Lin Chan (a2), Shu-I Wu (a3), Mong-Liang Lu (a4), Michael E. Dewey (a5), Robert Stewart (a6) and Charles Tzu-Chi Lee (a7)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.